Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00998556
Other study ID # PPCM
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 2010
Est. completion date August 2016

Study information

Verified date September 2020
Source Hannover Medical School
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, controlled clinical trial to evaluate the efficacy and safety of bromocriptine for improvement of left ventricular function of women with Peripartum cardiomyopathy (PPCM). A Multi center trial in Germany.


Description:

Peripartum cardiomyopathy (PPCM) is a serious life threatening heart disease of unknown etiology in previously healthy women. Only a minority of patients recovers completely while the majority of PPCM patients develop persistent ventricular dysfunction and may experience severe heart failure leading to cardiac transplantation. Thus, these young patients are very sick at a time when the newborn would need a healthy mother. Many of PPCM patients need lifelong treatment causing a large financial and social burden. Indeed, a better understanding of the disease and more efficient therapeutic options are urgently needed. To date, no specific therapy is available so that patients are treated by medical pharmacotherapy for heart failure.

Diagnosis of PPCM is usually made at advanced stages of the disease in severely symptomatic women but prognosis of affected women is poor with reported mortality rates of 15% and recovery in only 23% to 54% of PPCM patients despite optimal medical treatment. Therefore strategies are urgently needed to identify patients at risk and novel therapeutic approaches are required to improve poor prognosis of affected women.

The trial would establish a new specific therapeutic regimen for PPCM and the investigators can expect that such a novel approach would be rapidly adopted in the clinical management of this disease. Since the trial design follows state-of the-art guidelines, the investigators assume that bromocriptine would shortly be adopted into clinical guidelines of the German Cardiac Society, European Cardiac Society, and the American Heart Association.


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date August 2016
Est. primary completion date March 2016
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Female subjects in the first 5 months postpartum with new onset of left ventricular (LV) dysfunction (LV ejection fraction =35% as assessed by echocardiography) using the internationally accepted criteria for PPCM 1: absence of an identifiable cause of heart failure, absence of recognizable heart disease prior to the last month of pregnancy and LV systolic dysfunction demonstrated by classical echocardiographic criteria.

- Age equal or greater 18

- Written informed consent of the patient

Exclusion Criteria:

- Preexisting cardiac disease (except PPCM which had complete resolution in a previous pregnancy)

- Any preexisting serious conditions

- Previous cardiac surgery or percutaneous coronary intervention

- History of alcohol and/or any other drug abuse

- Contraindication to the planned therapy (e. g. hypersensitivity to trial medication or one of its components)

- Concomitant therapy other than specified in the trial protocol such as products for treatment of fungal infections, psychotropic drugs, medication with the active substances diclofenace, verapamil or doxycycline.

- Women with child bearing potency without effective contraception (i. e. implants, injectables, combined oral contraceptives, some IUDs or vasectomized partner) during the conduct of the trial. Patients using hormonal methods of contraception must be informed about possible influences of the study drug on contraception, in addition heart failure drugs may interfere with contraception. Patients will be counselled about the safest method to be used for contraception.

- Expected low compliance (e.g. by travel distance to trial site)

- Concomitant participation in other clinical trials

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bromocriptine
Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks. The study medication is taken on top of standard therapy for heart failure.

Locations

Country Name City State
Germany Hannover Medical School (MHH) Hannover Niedersachsen

Sponsors (2)

Lead Sponsor Collaborator
Hannover Medical School German Federal Ministry of Education and Research

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in left ventricular ejection fraction (LVEF) from baseline to six months follow-up Change in left ventricular ejection fraction (LVEF) from baseline to six months follow-up as assessed by cardiac Magnetic Resonance Imaging (MRI) & Echocardiography 6 months
Secondary Combined endpoint of hospitalization for heart failure, eligibility for cardiac transplantation, cardiac transplantation, and mortality during 6 months follow-up Combined endpoint of hospitalization for heart failure, eligibility for cardiac transplantation, cardiac transplantation, and mortality during 6 months follow-up; individual components of the combined endpoint; adverse events 6 months
See also
  Status Clinical Trial Phase
Completed NCT04144660 - "Treatment Use of ECMO In Pregnancy or Peripartum Patient."
Withdrawn NCT04143997 - Diastolic Dysfunction PPCM in Patients With Documented Left Ventricular Systolic Function Recovery
Completed NCT03081949 - Peripartum Cardiomyopathy in Nigeria Registry Phase 4
Recruiting NCT03364140 - A Registry of Peripartum Cardiomyopathy in Turkey N/A
Completed NCT04049136 - NT-proBNP Levels and Obesity in Pregnancy
Recruiting NCT04234659 - PPCM Observational Study (Peripartum Cardiomyopathy)
Withdrawn NCT02590601 - Bromocriptine in the Treatment of Peripartum Cardiomyopathy Phase 3
Completed NCT03907267 - Taurine in Peripartum Cardiomyopathy Phase 2/Phase 3
Recruiting NCT05878041 - Creation of a Multicenter National Registry for Peripartum Cardiomyopathy.
Recruiting NCT04927715 - Irisin Expression and Gene Polymorphism With Peripartum Cardiomyopathy.